Aug 8 (Reuters) - HLS Therapeutics Inc HLS.TO :
* HLS THERAPEUTICS ANNOUNCES Q2 2019 FINANCIAL RESULTS
* QTRLY REVENUE OF $13.6 MILLION
* Q2 LOSS PER SHARE $0.06
* TIMING OF CLOZARIL ORDERS ORDERS IMPACTED Q2 REVENUE BUT SHOULD HAVE A FAVORABLE IMPACT IN Q3
* AS AT JUNE 30, 2019, COMPANY HAD CASH AND CASH EQUIVALENTS OF $52.3 MILLION, UP FROM $10.9 MILLION AT DECEMBER 31, 2018